ArticleJCO precision oncology2024
Melanocortin-1 Receptor Expression as a Marker of Progression in Melanoma.
Article in JCO precision oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 9 citations in OpenAlex.
- Recent Developments in the Diagnosis and Treatment of Disseminated and Rare Melanoma with Radiotheranostics.ACS pharmacology & translational science · 2026Review
- Targeting Peptidergic Systems for Melanoma Treatment.Cancers · 2026Review
- MC1R contributes to ferroptosis resistance and tumor aggressiveness in colorectal cancer by activating Notch signaling.Cancer gene therapy · 2026Article
- Molecular and Genetic Markers for Malignant Melanoma: Implications for Prognosis and Therapy.Dermatopathology (Basel, Switzerland) · 2025Review
- Melanocortin-1 receptor expression as a predictive factor for postoperative outcomes in melanoma patients: a retrospective study.Frontiers in immunology · 2025Article
- GP100 expression is variable in intensity in melanoma.Cancer immunology, immunotherapy : CII · 2024Article
- Article
- Review
Corrections and comments
- Update of
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
purposeMelanocortin-1 receptor (MC1R) plays a critical role in human pigmentation and DNA repair mechanisms. MC1R-targeting agents are being investigated in clinical trials in patients with melanoma, yet large studies investigating the rate and degree of MC1R expression in primary and metastatic human melanoma tissue are lacking.
methodsUsing tissue microarrays containing three large cohorts of 225 cases of benign nevi, 189 with primary melanoma, and 271 with metastatic melanoma, we applied quantitative immunofluorescence and immunohistochemistry to comprehensively study MC1R protein expression.
resultsWe show a stepwise elevation of MC1R expression in different stages of melanoma progression (nevi, primary, metastasis). Higher MC1R expression was seen in deeper (>1 mm) primary lesions and ulcerated lesions and was associated with shorter survival in primary and metastatic tumors. On multivariable analysis, Breslow thickness, male sex, and chronic sun exposure were independent predictors of worse overall survival in the primary melanoma cohort.
conclusionOur data suggest that MC1R might be a valuable drug target in aggressive melanoma. Additional studies are warranted to determine its functional significance in melanoma progression and its utility as a predictive biomarker in patients receiving MC1R-directed therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.